Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 9, 2014

Waters, Chinese Pharmacopeia Commission Enter Drug QC Collab

  • Waters inked an agreement with the Chinese Pharmacopoeia Commission (ChP) to establish a joint open laboratory. The new lab will focus on in-depth research of pharmacopoeia standards, development of testing methods, and basic and advanced technical training of pharmacopoeia detection. It is scheduled to open before the end of this year.

    The new joint open laboratory—located in the Beijing Zhendong Guangming Drug Research Institute—is more than 1,300 square feet. The lab will be equipped with Waters chromatography and mass spectrometry technologies, including a range of ACQUITY UPLC® systems, ACQUITY UPC2® System, Xevo® tandem quadrupole and time-of-flight mass spectrometers, and a Natural Products Application Solution with UNIFI®.

    At the collaboration agreement signing ceremony in Beijing, Secretary General Zhang Wei of the ChP said "the ChP-Waters Joint Open Laboratory cooperation would become another milestone of the development of the ChP. This cooperation not only meets the needs of ChP’s own development, but also meets the demands of enhanced pharmacopoeia standards and improved public drug safety."

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »